In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

the state of health of patients with atrial fibrillation in the remote period after MAZE radiofrequency endocardial catheter ablation procedure

Session Poster Session III - Friday 08:30 - 12:30

Speaker Mikhail Khlynin

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2015

  • Topic : preventive cardiology
  • Sub-topic : Cardiovascular Rehabilitation
  • Session type : Poster Session

Authors : M S Khlynin (Tomsk,RU), ME Protasov (Tomsk,RU), RE Batalov (Tomsk,RU), SV Popov (Tomsk,RU), EA Protasova (Tomsk,RU)

Authors:
M S Khlynin1 , ME Protasov1 , RE Batalov1 , SV Popov1 , EA Protasova1 , 1Research Institute of Cardiology SB of RAMS - Tomsk - Russian Federation ,

Citation:

The aim of study was to evaluate the patients’ state of health by EQ-5D questionnaire before the "MAZE" radiofrequency endocardial catheter ablation procedure and in the remote period after it (36 months), according to the efficacy of the interventional treatment.

391 patients (247 male and 144 female) in the age from 18 to 77 years with atrial fibrillation (AF) were examined. All patients underwent catheter ablation, including pulmonary vein isolation, lines in the back wall, roof of the left atrium and the mitral isthmus. The state of health was evaluated, according to the efficacy of the interventional treatment and EQ-5D questionnaire data.

Results The efficacy of the ablation in patients with paroxysmal AF after 3 and 36 months was 92% and 83.3% correspondingly, in patients with persistent AF - 89.7% and 72.4% correspondingly. According to EQ-5D "thermometer", the state of health after 36 months was at the same level as at the beginning of the study if the catheter ablation was successful (79.74% and 81.4% in patients with paroxysmal AF; 79.94% and 81.06% in patients with persistent AF). But if the "MAZE" procedure was unsuccessful, there was a drop of the state of health from 80.8% to 70.14% in patients with paroxysmal AF and from 77.82% to 69.46% in patients with persistent AF. In the case of successful ablation there were no statistically significant changes in the mobility, usual activities, pain/discomfort, anxiety/depression initially and after 36 months of follow-up in patients with both paroxysmal and persistent AF (?=0,05). If the ablation was unsuccessful, the quantity of patients who had some problems in walking about increased from 38.5% (initially) to 61.1% (after 36 months) in patients with paroxysmal AF and from 71.9% to 92.9% in patients with persistent AF (?=0,05); the quantity of patients who had some problems with usual activities increased from 45.25% to 75% in group with paroxysmal AF and from 54.9% to 71.4% in group with persistent AF (?=0,05); patients with paroxysmal AF felt pain/discomfort initially in 45.6% cases, after 36 months – in 83.3%, with persistent AF in 71% and 85.7% correspondingly (?=0,05); anxiety/depression was initially in 39.75% of patients with paroxysmal AF and in 28.6% of patients with persistent AF, after 36 months – in 75% and 71.4% correspondingly (?=0,001). Self-care wasn’t changed in all groups of patients.

Conclusions The endocardial "MAZE" procedure in the remote period showed the efficacy in 83.3% in patients with paroxysmal AF, 72.4% in patients with persistent AF and helped to prevent the drop of the state of health

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are